Home > Archive > 2004 >

Volume 23 Number 3 (September/October)

Obesity, Insulin Resistance, and Cardiovascular Disease (pages 6-11)

Tracy McLaughlin, M.D., M.S.

Overweight and obesity increase risks for insulin resistance, but less than half of obese or overweight individuals are insulin resistant. This article shows you how you can identify your most at-risk overweight patients to better focus your time and most aggressive measures.
Complications and comorbiditiesCardiovascular disease
Complications and comorbiditiesObesity

Referral to Diabetes Self-Management Training and Medical Nutrition Therapy (pages 12-19)

Hope S. Warshaw, M.M.Sc., R.D., C.D.E., B.C.-A.D.M.

Medical nutrition therapy and self-management training are key parts of diabetes control, yet they are underutilized. In this article, the author discusses the effectiveness of these interventions and tells how to connect your patients to these resources.
Diet therapy and nutrition
EducationSelf-management strategies

Incretin Mimetics in the Treatment of Type 2 Diabetes (pages 20-27)

David Kendall, M.D., Sherry Martin, M.D., and Dennis Kim, M.D.

Incretin mimetics have shown potential for benefits such as enhancing glucose-mediated insulin secretion and reducing appetite. This article shows you the promise of these novel drugs that could one day serve as adjuncts to Type 2 diabetes treatment.
Drug treatmentIncretin mimetics

Managing Major Cardiovascular Risk Factors in Patients with Diabetes (pages 28-35)

Stephen N. Davis, M.D., F.R.C.P., James R. Sowers, M.D., Douglas E. Vaughan, M.D., F.A.C.C., and Donald S. Nelinson, Ph.D.

People with both hypertension and diabetes have twice the risks for cardiovascular diseases as people with hypertension alone. The authors present progressive treatment guidelines for your patients with hypertension that can help you to reduce their cardiovascular risks.
Complications and comorbiditiesCardiovascular disease

Footing the Bill (pages 39-40)

Daniel L. Lorber, M.D.

Enacted as a cost-neutral addition to Medicare, the therapeutic shoe benefit for at-risk people with diabetes may be becoming a victim of abuse. The Editor presents some of the recent research on the benefit of therapeutic shoes and argues that free shoes shouldn’t be a substitute for good foot care.
Health services and insurance